Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: A case report

Ma,Hongbing; Liu,Ting

doi:10.3892/ol.2016.4452

Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: A case report

Authors:
- Hongbing Ma
- Ting Liu
View Affiliations

Affiliations: Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: April 18, 2016 https://doi.org/10.3892/ol.2016.4452
Pages: 3858-3862

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Donor cell leukemia (DCL) is a rare complication of hematopoietic stem cell transplantation (HSCT) which occurs in ~5% of all leukemic relapses. In the English literature, >60 cases of DCL have been reported, however, only two cases of DCL following HSCT for the treatment of severe aplastic anemia (SAA) have been described to date. In the present study, the case of a 25 year‑old male patient diagnosed with SAA, who underwent a peripheral blood stem cell transplantation (PBSCT) using cells obtained from a sibling with an identical human leukocyte antigen, is presented. The patient developed acute myeloid leukemia with an (8;21)(q22;q22) translocation and an extra copy of the chromosome 8 in donor cells 2.5 years following PBSCT, which was preceded by the development of Graves' disease 1 year following PBSCT. The leukemia achieved complete remission following 1 cycle of priming therapy, 2 cycles of consolidation chemotherapy with daunorubicin and cytarabine and maintenance therapy with interleukin‑2 (IL‑2). At present, the patient has discontinued IL‑2 therapy, and the DCL has been in molecular remission for >3 years. The present case indicates that chemotherapy and IL‑2 maintenance therapy are an effective treatment for DCL; hyperthyroidism was relieved following treatment, although hypothyroidism subsequently developed.

View Figures

View References

1	Sala Torra O and Loeb KR: Donor cell-derived leukemia and myelodysplastic neoplasm: Unique forms of leukemia. Am J Clin Pathol. 135:501–504. 2011. View Article : Google Scholar : PubMed/NCBI
2	Wang E, Hutchison CB, Huang Q, Lu CM, Crow J, Wang FF, Sebastian S, Rehder C, Lagoo A, Horwitz M, et al: Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: A clinicopathologic study of 10 cases and a comprehensive review of the literature. Am J Clin Pathol. 135:525–540. 2011. View Article : Google Scholar : PubMed/NCBI
3	Wiseman DH: Donor cell leukemia: A review. Biol Blood Marrow Transplant. 17:771–789. 2011. View Article : Google Scholar : PubMed/NCBI
4	Browne PV, Lawler M, Humphries P and McCann SR: Donor-cell leukemia after bone marrow transplantation for severe aplastic anemia. N Engl J Med. 325:710–713. 1991. View Article : Google Scholar : PubMed/NCBI
5	Lawler M, Locasciulli A, Longoni D, Schiro R and McCann SR: Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia. Bone Marrow Transplant. 29:453–456. 2002. View Article : Google Scholar : PubMed/NCBI
6	Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip J, Yoshida N and Morilla R: A classification of acute leukaemia for the 1990s. Ann Hematol. 62:16–21. 1991. View Article : Google Scholar : PubMed/NCBI
7	Fialkow PJ, Thomas ED, Bryant JI and Neiman PE: Leukaemic transformation of engrafted human marrow cells in vivo. Lancet. 1:251–255. 1971. View Article : Google Scholar : PubMed/NCBI
8	Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S, Gratwohl A, Ferrant A, Elmaagacli A, Schwertfeger R, et al: Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation: Development of leukemia in donor cells after allogeneic stem cell transplantation - a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 90:969–975. 2005.PubMed/NCBI
9	Hashino S, Fujisawa F, Kondo T, Imamura M, Sato K, Torimoto Y, Kohgo Y, Kimura K, Furukawa H, Todo S and Asaka M: Donor-type myelodysplastic syndrome with t(2;3) and monosomy 7 after allogeneic peripheral blood stem cell transplantation and liver transplantation in a patient with severe-type aplastic anemia. Int J Hematol. 84:363–366. 2006. View Article : Google Scholar : PubMed/NCBI
10	Haltrich I, Müller J, Szabó J, Kovács G, Kóos R, Poros A, Dobos M and Fekete G: Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia. Cancer Genet Cytogenet. 142:124–128. 2003. View Article : Google Scholar : PubMed/NCBI
11	Ruiz-Argüelles GJ, Ruiz-Argüelles A and Garcés-Eisele J: Donor cell leukemia: A critical review. Leuk Lymphoma. 48:25–38. 2007. View Article : Google Scholar : PubMed/NCBI
12	Flynn CM and Kaufman DS: Donor cell leukemia: Insight into cancer stem cells and the stem cell niche. Blood. 109:2688–2692. 2007.PubMed/NCBI
13	Socié G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, McCann SR, Frickhofen N, Van't Veer-Korthof E and Gluckman E: European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party: Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med. 329:1152–1157. 1993. View Article : Google Scholar : PubMed/NCBI
14	Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, Kaneko T, Takano T, Ikuta K and Tsukimoto I: Japan Childhood Aplastic Anemia Study Group: Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 100:786–790. 2002. View Article : Google Scholar : PubMed/NCBI
15	Saracco P, Quarello P, Iori AP, Zecca M, Longoni D, Svahn J, Varotto S, Del Vecchio GC, Dufour C, Ramenghi U, et al: Bone Marrow Failure Study Group of the AIEOP (Italian Association of Paediatric Haematology Oncology): Cyclosporin A response and dependence in children with acquired aplastic anaemia: A multicentre retrospective study with long-term observation follow-up. Br J Haematol. 140:197–205. 2008. View Article : Google Scholar : PubMed/NCBI
16	Kaito K, Kobayashi M, Katayama T, Masuoka H, Shimada T, Nishiwaki K, Sekita T, Otsubo H, Ogasawara Y and Hosoya T: Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol. 103:297–303. 1998. View Article : Google Scholar : PubMed/NCBI
17	Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J, Deeg HJ, Doney K, Thomas D, Storb R and Thomas ED: Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med. 321:784–789. 1989. View Article : Google Scholar : PubMed/NCBI
18	Moore KA and Lemischka IR: Stem cells and their niches. Science. 311:1880–1885. 2006. View Article : Google Scholar : PubMed/NCBI
19	Li Z and Li L: Understanding hematopoietic stem-cell microenvironments. Trends Biochem Sci. 31:589–595. 2006. View Article : Google Scholar : PubMed/NCBI
20	Zhang SR, Salup RR, Urias PE, Twilley TA, Talmadge JE, Herberman RB and Wiltrout RH: Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2. Cancer Immunol Immunother. 21:19–25. 1986. View Article : Google Scholar : PubMed/NCBI